Actualités

LLY, HSBC and PLTR headline new research as growth drivers, strategic initiatives and key risks shape the latest outlooks for these companies.

While rivals scramble to replace lost revenue, Lilly is opening an unprecedented gap by being a “contrarian,” as one expert says.

Eli Lilly (NYSE:LLY) has entered a new research collaboration with Abbisko Cayman Limited, focused on expanding its pipeline through external R&D partnerships. The company has transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics, adjusting its approach in that market. Eli Lilly has become closely associated with obesity and diabetes treatments, but this latest update shows the company putting more emphasis on partnerships and regional focus. The Abbisko...

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -1.14% move from the preceding trading day.

Eli Lilly, HSBC and Palantir headline Zacks' latest top stock reports, highlighting growth drivers, opportunities and key risks shaping each outlook.

Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.

Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, are worth a look.

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

As the Nasdaq shakes off a recent spat of volatility, Eli Lilly, Affirm. Twilio and BillionToOne come into focus.

Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.

Abivax (ABVX) shares have rebounded to pre-Phase 3 maintenance data levels as investor concerns over

ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q1 2026 investor letter. A copy of the letter can be downloaded here. The US stock market declined in the quarter with the S&P 500 index (“S&P”) and the Russell 1000 Growth index (“RLG”) […]

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Lilly offers investors safety and growth.

Eli Lilly (LLY) climbed to new record highs in the final week of June, driven by strong sales of its weight-loss drugs. Away from that spotlight, the drugmaker made changes to a smaller corner of its business in its second-largest market. On June 30, Lilly agreed to hand a Chinese partner full ...

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Eli Lilly stock has surged over the past five years, and at around US$1,213 a share, investors are weighing a sharp share price gain against signals that the stock screens as expensive on several checks even as a Discounted Cash Flow (DCF) estimate points to upside. A roughly 441.5% return over five years puts Eli Lilly among the stronger long term performers, which raises the bar for what counts as an attractive entry point. Expectations around the GLP-1 obesity and diabetes franchise can...

Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now. GLP-1 Fireworks ... Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly

The stock is known to soar on good news.

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.

Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.

Healthcare stocks are attracting attention in a market broadening beyond AI-driven tech names, and now make up a big chunk of the IBD 50 list.

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...

LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.

Medicare is now covering weight-loss drugs for some seniors, in a win for patients. For Wall Street, the math is trickier.

GLP-1s will fuel the industry’s growth in the coming years if outside forces don’t get in the way.